Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis

Company Overview

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.

Key Stats

• Today's Range: $9.50 to $9.86
• 50-Day Range: $8.77 to $10.74
• 52-Week Range: $8.65 to $13.00
• Volume: 3,092 shs
• Average Volume: 9,816 shs
• Market Capitalization: N/A
• P/E Ratio: 0.09
• Dividend Yield: 489.84%
• Price Target: N/A
• Consensus Rating: N/A

Santen Pharmaceutical Stock Analysis - MarketRank™

Santen Pharmaceutical scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Santen Pharmaceutical.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.12.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Santen Pharmaceutical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Santen Pharmaceutical has recently decreased by 55.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Santen Pharmaceutical pays a meaningful dividend of 1.47%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Santen Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Santen Pharmaceutical is 46.34%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Santen Pharmaceutical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Santen Pharmaceutical has recently decreased by 55.56%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Santen Pharmaceutical has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Santen Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.05% of the stock of Santen Pharmaceutical is held by institutions.

SNPHY Stock Analysis - Frequently Asked Questions

How have SNPHY shares performed this year?

Santen Pharmaceutical's stock was trading at $10.12 on January 1st, 2025. Since then, SNPHY shares have decreased by 2.6% and is now trading at $9.86.
View the best growth stocks for 2025 here.

How do I buy shares of Santen Pharmaceutical?

Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 4/02/2025
• Next Earnings (Estimated): 5/07/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SNPHY
• CIK: 1501108
• Web: www.santen.com
• Phone: (167) 664-8621
• Fax: N/A
• Employees: 4,144
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.09
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A